Form 4: Exponent CEO Granted 28,500 Stock Options

Exponent Inc.'s President and CEO, Catherine Corrigan, was granted 28,500 stock options at an exercise price of $70.16, vesting over four years.

Summary

• Catherine Corrigan, President & CEO and Director of Exponent Inc. (EXPO), was granted a total of 28,500 stock options on February 20, 2026.
• The grant comprises 1,425 Incentive Stock Options and 27,075 Non-Qualified Stock Options.
• All options have an exercise price of $70.16 per share.
• The options will become exercisable in four equal annual installments, commencing from the grant date.
• The expiration date for these stock options is February 20, 2036.
• This transaction was executed pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a standard and expected executive compensation disclosure, reflecting ongoing management incentives and commitment to the company's long-term performance.

Positives

• The grant of stock options aligns the interests of the CEO with shareholders, incentivizing long-term company performance and value creation.
• A four-year vesting schedule encourages sustained leadership and commitment from the CEO.
• The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged and compliant approach to insider trading.

Negatives

• Potential for future share dilution if all options are exercised, which is a standard consideration with equity-based compensation.

Risks

• Future exercise of these options could lead to a slight dilution of existing shareholder equity, impacting earnings per share.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding company performance, but the long-term vesting of options suggests an expectation of continued executive tenure and future value creation.

Management Comments

• The stock option becomes exercisable in four equal annual installments.

Industry Context

StockSavvy.ai notes that granting stock options with multi-year vesting schedules is a common practice in the professional and technical services industry, similar to firms like FTI Consulting or Huron Consulting Group, to retain key executives and align their incentives with long-term shareholder value creation. The exercise price typically reflects the market price on the grant date, ensuring the options only gain value if the stock price appreciates.

Comparison to Industry Standards

• The grant of 28,500 stock options to a CEO of a company like Exponent Inc. is generally within the range of executive compensation packages seen in the specialized consulting and engineering services sector. For instance, CEOs at comparable firms such as CRA International or Berkeley Research Group often receive a mix of base salary, cash bonuses, and equity awards (including stock options and restricted stock units) designed to incentivize performance and retention.
• The four-year vesting schedule is a standard industry practice, aligning with typical executive retention periods and long-term strategic planning cycles, similar to what is observed at publicly traded peers.
• The use of a Rule 10b5-1 plan for the transaction is a best practice for insiders to avoid accusations of trading on material non-public information, a standard adopted across most public companies.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for slight future dilution if options are exercised, but also increased alignment of CEO's interests with shareholder value creation.
• **Employees**: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.
• **Management**: Provides a significant long-term incentive for the CEO to drive company performance.

Next Steps

• The stock options will become exercisable in four equal annual installments starting February 20, 2026.
• Catherine Corrigan may choose to exercise these options at any point after they vest and before their expiration date of February 20, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine grant of stock options to the CEO as part of her compensation package. While it aligns management's interests with shareholders, it does not present new information that would fundamentally alter the investment thesis for Exponent Inc. Therefore, a 'hold' recommendation is appropriate, as the filing itself does not provide a strong catalyst for either buying or selling the stock.

Keywords

Exponent Inc., EXPO, Catherine Corrigan, Stock Options, Executive Compensation, Form 4, Insider Transaction, Rule 10b5-1, Corporate Governance